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GSK3β signaling pathway
Lei Zhang1,2,3, Jie Zhang1,4, Yuanlin Dong1, Celeste A Swain1, Yiying Zhang1 and Zhongcong Xie1*Abstract
Background: Anesthesia with multiple exposures of commonly used inhalation anesthetic sevoflurane induces
neuroinflammation and cognitive impairment in young mice, but anesthesia with a single exposure to sevoflurane
does not. AKT/glycogen synthase kinase 3β (GSK3β) signaling pathway is involved in neurotoxicity and
neurobehavioral deficits. However, whether sevoflurane can induce a dual effect (increase versus decrease) on the
activation of AKT/GSK3β signaling pathway remains to be determined. We therefore set out to assess the effects of
sevoflurane on AKT/GSK3β signaling pathway in vivo and in vitro.
Methods: Six day-old wild-type mice were exposed to 3% sevoflurane two hours daily for one or three days. In the
in vitro studies, H4 human neuroglioma cells were treated with 4% sevoflurane for two or six hours. We then
determined the effects of different sevoflurane treatments on the levels of phosphorylated (P)-GSK3β(ser9) and
P-AKT(ser473) by using Western blot analysis.
Results: Here we show that anesthesia with 3% sevoflurane two hours daily for one day increased the levels of
P-GSK3β(ser9) and P-AKT(ser473), but the anesthesia with 3% sevoflurane daily for three days decreased them in the
mice. The treatment with 4% sevoflurane for two hours increased, but the treatment with 4% sevoflurane for six
hours decreased, the levels of P-GSK3β(ser9) and P-AKT(ser473) in the H4 human neuroglioma cells.
Conclusions: Anesthetic sevoflurane might induce a dual effect (increase versus decrease) on the activation of the
AKT/GSK3β signaling pathway. These studies have established a system to perform further studies to determine the
effects of sevoflurane on brain function.
Keywords: Anesthetic, Sevoflurane, Phosphorylation, AKT/GSK3β signaling pathwayIntroduction
There are approximately six million children who undergo
surgical care under anesthesia each year in America alone
[1]. The increased use of anesthetics in children makes the
safety of anesthesia a major health issue in the United
States and in the world [[2], reviewed in [3]]. Several clinical
studies have shown that anesthesia and surgery could be
risk factors for subsequent cognitive impairment [reviewed
in [3]]. Specifically, children may develop cognitive defi-
ciency following multiple exposures (e.g., three times) to
anesthesia and surgery at an early age (e.g., before age 4)
[[4,5], reviewed in [3]]. These findings have become a major* Correspondence: zxie@mgh.harvard.edu
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unless otherwise stated.public health issue [2], and have promoted more clinical
and pre-clinical investigations.
In the animal studies, it has been reported that anesthesia
may induce neurotoxicity and neurobehavioral deficits in
rodents [6-8] and monkeys [9,10] [reviewed in [3]]. A re-
cent study has shown that anesthesia with 3% sevoflurane
two hours daily for three, but not one, days induces neuro-
inflammation and cognitive impairment in young (six day-
old) mice [11]. These studies suggested that sevoflurane
might have dual effects on neurotoxicity and cognitive
function.
Glycogen synthase kinase 3β (GSK3β) has been reported
to contribute to Alzheimer’s disease neuropathogenesis, in-
cluding β-amyloid protein and Tau [12], apoptosis, neuroin-
flammation, oxidative stress, acetylcholine activity, axon
degeneration, and axonal transport, leading to cognitive im-
pairment [[13–16], reviewed in [17]].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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phosphorylation under normal physiological conditions.
The activated AKT [phosphorylated AKT (P-AKT)] then
phosphorylates substrates, including GSK3β, to phos-
phorylated substrates, e.g., phosphorylated GSK3β (P-
GSK3β) [18]. Specifically, AKT phosphorylates GSK3β at
ser9 and the P-GSK3β (ser9), leading to decreased activ-
ity of GSK3β [19,20].
Activation of the AKT/GSK3β signaling pathway, demon-
strated as increases in the levels of P-AKT(ser473) and P-
GSK3β(ser9), has been reported to protect against myocar-
dial apoptosis induced by ischemia/reperfusion in rats [21]
and to increase the survival of hippocampal neurons fol-
lowing ischemia in rats [22,23].
We therefore set out to investigate the potential dual
effects of sevoflurane anesthesia on the AKT/GSK3β sig-
naling pathway in young (six day-old) wild-type mice
and in H4 human neuroglioma cells (H4 cells). The hy-
pothesis in the study is that single exposure or short
duration treatment with sevoflurane increases, but mul-
tiple exposures or long duration treatment with sevoflur-
ane decreases, the levels of P-GSK3β and P-AKT. We
used 3% sevoflurane in the animal studies because our
previous studies showed that anesthesia with 3% sevo-
flurane two hours daily for three days, but not one day,
was able to induce neuroinflammation and cognitive im-
pairment in mice [11]. We used 4% sevoflurane in the
in vitro studies because our previous in vitro studies
showed the treatment with 4% sevoflurane for six hours
could induce apoptosis and increase Aβ levels in the hu-
man H4 neuroglioma cells [24].
Materials and methods
Mice anesthesia and treatment
All experiments were performed in accordance with the
National Institute of Health guidelines and regulations. The
animal protocol was approved by the Massachusetts Gen-
eral Hospital Standing Committee on the Use of Animals
in Research and Teaching (Boston, Massachusetts). Efforts
were made to minimize the number of animals used.
Both male and female mice (C57BL/6J, Jackson Lab,
Bar Harbor, ME) were used in the studies. Young mice
(six day-old) were used in the current studies. The mice
were randomly assigned into the anesthesia group or the
control group. The mice received the sevoflurane at
postnatal day (P) 6 or from P6 to P8. The mice received
anesthetic sevoflurane (3%) plus 60% oxygen (balanced
with nitrogen) as performed in our previous studies
[11,25]. The 60% oxygen maintains sufficient partial
pressure of oxygen levels in the mice during anesthesia
as demonstrated in previous studies [7,11,25]. The size
of the induction chamber in the current study was 20 ×
20 × 7 centimeters. The induction flow rate was 2 liters
per minute for the first three minutes (for the induction)and then one liter per minute (for maintenance). Control
group received 60% oxygen at an identical flow rate in simi-
lar chambers. The anesthetic and oxygen concentrations
were measured continuously by a gas analyzer (Ohmeda,
GE Healthcare, Tewksbury, MA). The temperature of
the anesthetizing chamber was controlled by the DC
Temperature Control System (FHC, Bowdoinham, Maine),
which is a feedback based system for monitoring and con-
trolling temperature, to maintain the rectal temperature of
the mice as 37 ± 0.5°C. Previous studies [7,11,25] have
shown that anesthesia with 3% sevoflurane for two hours
did not significantly change the values of pH, partial pres-
sure of oxygen, or partial pressure of carbon dioxide as
compared to the control group. Mortality rate of mice in
these studies was less than 1%.
Cell lines and treatment
We employed H4 human neuroglioma cells (H4 cells) in
the experiments. The cells were cultured in DMEM
(high glucose) containing 9% heat-inactivated fetal calf
serum, 100 units/ml penicillin, 100 μg/ml streptomycin,
and 2 mM L-glutamine. The cells were treated with 21%
O2, 5% CO2 and 4% [2 minimum alveolar concentration
(MAC)] sevoflurane for two or six hours, as described
by Dong et al. [24]. 21% O2, 5% CO2 and 4% sevoflurane
were delivered from an anesthesia machine to a sealed
plastic box in a 37°C incubator containing six-well plates
seeded with one million cells in 1.5 ml cell culture
media. A Datex infrared gas analyzer (Ohmeda, GE
Healthcare) was used to continuously monitor the con-
centrations of delivered carbon dioxide, oxygen, and
sevoflurane as performed in our previous studies [24].
Harvest of brain tissues and cells, and protein level
quantification
Following the anesthesia, the mice were killed by decapi-
tation at P8. The brain tissues were harvested and sub-
jected to Western blot analysis. The H4 cells were
harvested in the end of the sevoflurane treatment or
control condition. The harvested brain tissues and H4
cells were homogenized on ice using immunoprecipita-
tion buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl,
2 mM EDTA, 0.5% Nonidet P-40) plus protease inhibi-
tors (1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pep-
statin A). The lysates were collected, centrifuged at
12,000 rpm for 10 minutes, and quantified for total pro-
teins with bicinchoninic acid protein assay kit (Pierce,
Iselin, NJ).
Western blot analysis
GSK3β antibody (1:1,000 dilution, Cell Signaling
Technology, #9336, Danvers, MA) was used to recognize
P-GSK3β(ser9) (46 kDa). P-AKT(ser473) was recognized
by P-AKT(ser473) antibody (60 kDa, 1:1,000, Cell
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detect non-targeted protein β-Actin (42 kDa, 1:5,000,
Sigma, St. Louis, MO) was used to control for loading
differences in total protein amounts. Western blot quan-
tification was performed as described by Zhang et al.
[26]. Briefly, signal intensity was analyzed using image
analysis program Quantity One (Bio-Rad, Hercules, CA).
We quantified the Western blots in two steps, first using
β-Actin levels to normalize protein levels (e.g., determin-
ing the ratio of P-GSK3β to β-Actin amount) and con-
trol for loading differences in the total protein amount.
Second, we presented protein level changes in mice
undergoing sevoflurane anesthesia as a percentage of
those in the control condition. 100% of protein level
changes refer to control levels for the purpose of com-
parison to experimental conditions.
Statistics
Data were expressed as mean ± standard deviation (SD).
Each group had 6 mice or wells of cells. We performed a
power analysis based on our previous studies [11,24],
and found that a sample size of 6 per arm would lead to
a 90% power to detect a difference in the behavioral
changes using a two-sided t-test with 5% type I error.
Given the presence of background AKT/GSK3β activa-
tion in cells and brain tissues of mice, we did not use ab-
solute values to describe these changes. Instead, these
changes were presented as percentages of those from the
control group. For example, one hundred percent of
AKT refers to the control level for the purpose of com-
parison to experimental conditions. Student’s t-test was
used to determine the difference between the sevoflur-
ane anesthesia and control condition in the levels of P-
GSK3β and P-AKT. P values less than 0.05 were consid-
ered statistically significant. Prism 6 software (La Jolla,
CA) was used to analyze the data.
Results
Single exposure with sevoflurane anesthesia in young WT
mice increased the levels of P-GSK3β(ser9) and P-AKT
(ser473) in brain tissues of the mice
Activation of AKT/GSK3β signaling pathway, demon-
strated as increases in the levels of P-GSK3β(ser9) and
P-AKT(ser473), has been reported to protect cellular
toxicity [21-23]. We therefore set out to study the effects
of sevoflurane anesthesia on the levels of P-GSK3β(ser9)
and P-AKT(ser473).
P-GSK3β(ser9) immunoblotting showed that there was
a visible increase in the levels of P-GSK3β(ser9) in brain
tissues of the mice treated with sevoflurane (lanes 4 to
6) as compared to that of the mice treated with the con-
trol condition (lanes 1 to 3) (Figure 1A). There was no
significant difference in the β-Actin levels in the brain
tissues of the mice treated with sevoflurane as comparedto that of the mice treated with the control condition
(Figure 1A). Quantification of the Western blot, based
on the ratio of P-GSK3β(ser9) levels to β-Actin levels,
showed that the sevoflurane anesthesia (black bar) in-
creased the P-GSK3β(ser9) levels as compared to the
control condition (white bar): 182% versus 100%, P =
0.005 (Student t-test) (Figure 1B).
Next, we assessed the effects of the sevoflurane
anesthesia on P-AKT(ser473) levels in the brain tissues
of mice. P-AKT(ser473) immunoblotting showed that
there was a visible increase in the levels of P-AKT
(ser473) in brain tissues of the mice treated with sevo-
flurane (lanes 4 to 6) as compared to that of the mice
treated with the control condition (lanes 1 to 3)
(Figure 1C). There was no significant difference in the β-
Actin levels between the sevoflurane anesthesia and the
control condition (Figure 1C). Quantification of the
Western blot, based on the ratio of P-AKT(ser473) levels
to β-Actin levels, showed that the sevoflurane anesthesia
(black bar) increased the P-AKT(ser473) levels as com-
pared to control condition (white bar): 153% versus
100%, P = 0.015 (Student t-test) (Figure 1D).
Multiple exposures with sevoflurane anesthesia in young
WT mice decreased the levels of P-GSK3β(ser9) and P-AKT
(ser473) in the brain tissues of the mice
Our previous studies have shown that anesthesia with
3% sevoflurane two hours daily for one day in P6 does
not induce cognitive impairment in the mice at P30.
However, the anesthesia with 3% sevoflurane two hours
daily for three days (from P6 to P8) is able to induce
cognitive impairment in the mice at P30 [11]. Given that
single sevoflurane anesthesia increased the levels of P-
GSK3β(ser9) and P-AKT(ser473), next, we assessed the
effects of multiple exposures with sevoflurane anesthesia
on the levels of P-GSK3β(ser9) and P-AKT(ser473) in
the brain tissues of young mice.
P-GSK3β(ser9) immunoblotting demonstrated a visible
decrease in the levels of P-GSK3β(ser9) in brain tissues
of the mice treated with the sevoflurane anesthesia
(lanes 4 to 6) as compared to that of the mice treated
with control condition (lanes 1 to 3) (Figure 2A). There
was no significant difference in the β-Actin levels be-
tween the sevoflurane anesthesia and the control condi-
tion (Figure 2A). Quantification of the Western blot,
based on the ratio of P-GSK3β(ser9) levels to β-Actin
levels, indicated that the sevoflurane anesthesia (black
bar) decreased the P-GSK3β(ser9) levels as compared
to control condition (white bar): 37% versus 100%,
P = 0.0004 (Student t-test) (Figure 2B).
The Western blot analysis also showed that the
anesthesia with 3% sevoflurane two hours daily for three
days (lanes 4 to 6) decreased the levels of P-AKT
(ser473) as compared to the control condition (lanes 1
Figure 1 Single sevoflurane anesthesia in P6 mice increases levels of P-GSK3β(ser9) and P-AKT(ser473) in brain tissues. A. Anesthesia
with 3% sevoflurane two hours daily for one day in P6 mice increases the levels of P-GSK3β(ser9) in the brain tissues of the mice as compared to
the control condition. There is no significant difference in β-Actin levels in the brain tissues of the mice between the sevoflurane anesthesia and
control condition. B. Quantification of the Western blot shows that the sevoflurane anesthesia increases the levels of P-GSK3β(ser9) in the brain
tissues of the mice as compared to the control condition. C. Anesthesia with 3% sevoflurane two hours daily for one day in P6 mice increases the
levels of P-AKT(ser473) in the brain tissues of the mice as compared to the control condition. There is no significant difference in β-Actin levels in
the brain tissues of the mice between the sevoflurane anesthesia and control condition. D. Quantification of the Western blot shows
that the sevoflurane anesthesia increases the levels of P-AKT(ser473) in the brain tissues of the mice as compared to the control condition.
P, phosphorylated; GSK3β, glycogen synthase kinase 3β. N = 6.
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nificant difference in the β-Actin levels in the brain tis-
sues between the sevoflurane anesthesia and control
condition. The quantification of the Western blot dem-
onstrated that the sevoflurane anesthesia (black bar) de-
creased the levels of P-AKT(ser473): 53% versus 100%,
P = 0.0017 (Student t-test) (Figure 2D).
These findings suggested that the single exposure with
3% sevoflurane anesthesia for two hours increased the
levels of P-GSK3β(ser9) and P-AKT(ser473) as com-
pared to the control condition, but the multiple (three
times) exposures with 3% sevoflurane anesthesia for two
hours decreased the levels of P-GSK3β(ser9) and P-AKT
(ser473), as compared to the control condition in the
brain tissues of young mice.
Short time treatment with sevoflurane in H4 cells
increased the levels of P-GSK3β(ser9) and P-AKT(ser473)
in the H4 cells
Given the findings that there was a difference in the
levels of P-GSK3β(ser9) and P-AKT(ser473) between
single (two hours) and multiple (three two hour) expo-
sures of anesthesia with sevoflurane in the brain tissues
of mice, next, we asked whether such difference was
owing to multiple exposures to sevoflurane or was alsoowing to the longer duration of anesthesia. It is difficult
to anesthetize young mice with 3% sevoflurane for six
hours because such anesthesia was reported to induce
high mortality rate [25]. Therefore, we assessed the
potential different effects between two hours and six
hours anesthesia with sevoflurane on the levels of
P-GSK3β(ser9) and P-AKT(ser473) in H4 cells.
P-GSK3β(ser9) immunoblotting showed a visible increase
in the levels of P-GSK3β(ser9) in the H4 cells treated with
4% sevoflurane for two hours (lanes 4 to 6) as compared to
that of the cells treated with the control condition (lanes 1
to 3) (Figure 3A). There was no significant difference in the
β-Actin levels in the H4 cells treated with sevoflurane as
compared to that of the H4 cells treated with the control
condition (Figure 3A). Quantification of the Western blot,
based on the ratio of P-GSK3β(ser9) levels to β-Actin levels,
showed that the sevoflurane treatment (black bar) increased
the P-GSK3β(ser9) levels as compared to the control condi-
tion (white bar): 277% versus 100%, P = 0.011 (Figure 3B)
(Student t-test).
The Western blot analysis showed that the treatment
with 4% sevoflurane for two hours (lanes 4 to 6) also in-
creased P-AKT(ser473) levels as compared to the control
condition (lanes 1 to 3) in the H4 cells (Figure 3C). There
was no significant difference in the β-Actin levels between
Figure 2 Multiple sevoflurane anesthesia in P6 mice decreases levels of P-GSK3β(ser9) and P-AKT(ser473) in brain tissues. A. Anesthesia
with 3% sevoflurane two hours daily for three days in P6 mice decreases the levels of P-GSK3β(ser9) in the brain tissues of the mice as compared
to the control condition. There is no significant difference in β-Actin levels in the brain tissues of the mice between the sevoflurane anesthesia
and control condition. B. Quantification of the Western blot shows that the sevoflurane anesthesia decreases the levels of P-GSK3β(ser9) in the
brain tissues of the mice as compared to the control condition. C. Anesthesia with 3% sevoflurane two hours daily for three days in P6 mice
decreases the levels of P-AKT(ser473) in the brain tissues of the mice as compared to the control condition. There is no significant difference in
β-Actin levels in the brain tissues of the mice between the sevoflurane anesthesia and control condition. D. Quantification of the Western blot
shows that the sevoflurane anesthesia decreases the levels of P-AKT(ser473) in the brain tissues of the mice as compared to the control condition.
P, phosphorylated; GSK3β, glycogen synthase kinase 3β. N = 6.
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(Figure 3C). Quantification of the Western blot, based on
the ratio of P-AKT(ser473) levels to β-Actin levels, showed
that the sevoflurane treatment (black bar) increased the P-
AKT(ser473) levels as compared to the control condition
(white bar) in the H4 cells: 188% versus 100%, P = 0.006
(Student t-test) (Figure 3D).
Long time treatment with sevoflurane in H4 cells
decreased the levels of P-GSK3β(ser9) and P-AKT(ser473)
in the H4 cells
Finally, we asked whether long time treatment with sevo-
flurane might have different effects on the levels of P-
GSK3β(ser9) and P-AKT(ser473) in the H4 cells. The
Western blot analysis showed that the treatment with 4%
sevoflurane for six hours (lanes 4 to 6) reduced the levels of
both P-GSK3β(ser9) and P-AKT(ser473) as compared to
the control condition (lanes 1 to 3) in the H4 cells
(Figure 4A). There was no significant difference in the β-Actin levels between the sevoflurane treatment and the
control condition (Figure 4A). The quantification of the
Western blot, based on the ratio of the P-GSK3β(ser9) and
P-AKT(ser473) levels to the β-Actin levels, showed that the
sevoflurane treatment (4% and six hours, black bar) de-
creased the levels of P-GSK3β(ser9) (Figure 4B, 57% versus
100%, P = 0.011, Student t-test) and P-AKT(ser473) (Fig-
ure 4C, 52% versus 100%, P = 0.028, Student t-test) as com-
pared to the control condition (white bar).
Taken together, these data suggested that different du-
rations (two versus six hours) of sevoflurane treatment
in H4 cells and different exposures of sevoflurane
anesthesia (one versus three times) in mice could lead to
varying effects (increase versus reduction) on the levels
of P-GSK3β(ser9) and P-AKT(ser473).
Discussion
Sevoflurane is the most commonly used anesthetic in chil-
dren. Sevoflurane has been shown to induce apoptosis
Figure 3 Short sevoflurane treatment increases the levels of P-GSK3β(ser9) and P-AKT(ser473) in H4 cells. A. Anesthesia with 4%
sevoflurane for two hours increases the levels of P-GSK3β(ser9) in the H4 cells as compared to the control condition. There is no significant
difference in β-Actin levels in the H4 cells between the sevoflurane anesthesia and control condition. B. Quantification of the Western blot shows
that the sevoflurane anesthesia increases the levels of P-GSK3β(ser9) in the H4 cells as compared to the control condition. C. Anesthesia with 4%
sevoflurane for two hours in H4 cells increases the levels of P-AKT(ser473) in the H4 cells as compared to the control condition. There is no
significant difference in β-Actin levels in the H4 cells between the sevoflurane anesthesia and control condition. D. Quantification of the Western
blot shows that the sevoflurane anesthesia increases the levels of P-AKT(ser473) in the H4 cells as compared to the control condition.
P, phosphorylated; GSK3β, glycogen synthase kinase 3β. N = 6.
Zhang et al. Medical Gas Research 2014, 4:5 Page 6 of 9
http://www.medicalgasresearch.com/content/4/1/5[7,25], increase β-amyloid protein levels [25] and neuroin-
flammation [11], leading to cognitive impairment in young
mice [7,11,25]. Specifically, anesthesia with 3% sevoflurane
two hours daily for three days induces neuroinflammation
and cognitive impairment, while anesthesia with 3% sevo-
flurane two hours daily for one day does not [11]. These
data suggested that anesthetic sevoflurane might cause dual
effects on neurotoxicity and cognitive function. However,
whether sevoflurane anesthesia can induce dual effects on
AKT/GSK3β signaling pathway remains to be determined.
We first found that anesthesia with 3% sevoflurane
two hours daily for one day increased the levels of P-
GSK3β(ser9) and P-AKT(ser473) (Figure 1). These data
indicated that the single exposure to sevoflurane might
enhance the activation of the AKT/GSK3β signaling
pathway. However, the anesthesia with 3% sevoflurane
two hours daily for three days reduced the levels of P-
GSK3β(ser9) and P-AKT(ser473) (Figure 2). These re-
sults showed that the multiple exposures to sevoflurane
decreased the activation of the AKT/GSK3β signaling
pathway. These findings suggested that single (two
hours) and multiple (three times of two hours)exposures with sevoflurane anesthesia could increase
and decrease the activation of AKT/GSK3β signaling
pathway, respectively, potential dual effects of sevoflur-
ane on the AKT/GSK3β signaling pathway. The future
studies might include a different anesthesia regimen to
further test this hypothesis. We would assess whether
anesthesia with 3% sevoflurane two hours weekly for one
or three weeks might have different effects on the AKT/
GSK3β signaling pathway as well as other behavioral and
brain biochemistry changes.
Such a difference could result from single versus mul-
tiple exposures to sevoflurane or from shorter versus
longer durations of anesthesia. Anesthetizing young
mice with 3% sevoflurane for six hours could lead to a
high mortality rate [25]. Therefore, H4 cells were used
to assess the potential difference of short versus long
duration of sevoflurane anesthesia on the levels of P-
GSK3β(ser9) and P-AKT(ser473).
We were able to show that the treatment with 4%
sevoflurane for two hours increased, but the treatment
with 4% sevoflurane for six hours decreased, the levels
of P-GSK3β(ser9) and P-AKT(ser473). These data
Figure 4 Long sevoflurane treatment decreases the levels of P-GSK3β(ser9) and P-AKT(ser473) in H4 cells. A. Anesthesia with 4%
sevoflurane for six hours decreases the levels of P-GSK3β(ser9) and P-AKT(ser473) in the H4 cells as compared to the control condition. There is
no significant difference in β-Actin levels in the H4 cells between the sevoflurane anesthesia and control condition. B. Quantification of the
Western blot shows that the sevoflurane anesthesia decreases the levels of P-GSK3β(ser9) in the H4 cells as compared to the control condition. C.
Quantification of the Western blot shows that the sevoflurane anesthesia decreases the levels of P-AKT(ser473) in the H4 cells as compared to the
control condition. N = 6.
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cells and that a short duration of sevoflurane anesthesia
increased the activation of the AKT/GSK3β signaling
pathway, but a long duration of sevoflurane anesthesia
decreased it.
Phosphorylation at serine 9 of GSK3β inhibits the ac-
tivity of GSK3β [27-32]. The current findings that the
short exposure time to sevoflurane anesthesia increased
P-GSK3β(ser9) levels, but the longer exposure to sevo-
flurane anesthesia exposure decreased P-GSK3β(ser9)
levels, indicates that the short exposure time to sevoflur-
ane anesthesia reduced, but the longer exposure time to
sevoflurane enhanced the activity of GSK3β, respectively.
Taken together, these findings suggested that the dual
effects of sevoflurane on AKT/GSK3β signaling pathway
and that a short exposure time to sevoflurane treatment
might produce neuroprotection via activation of AKT/
GSK3β signaling pathway, but a long exposure time to
sevoflurane anesthesia could induce neurotoxicity via in-
hibition of AKT/GSK3β signaling pathway. Interestingly,
while long durations (e.g., three time of two hours) of
sevoflurane anesthesia induced cognitive impairment,
the shorter exposure time (e.g., one time of two hours)of sevoflurane anesthesia did not improve the learning
and memory function in the mice [11]. It is conceivable
that the short exposure time to sevoflurane anesthesia
may only produce neuroprotection when there is a brain
insult. This hypothesis has been supported by the out-
comes from the previous studies which show that sevo-
flurane has neuroprotective effects [reviews in [33,34]].
The findings that sevoflurane may have dual effects
(neuroprotection versus neurotoxicity) would be import-
ant to further determine the role of sevoflurane in brain
function. In addition, our studies showed that the AKT/
GSK3β could be one of the cellular mechanisms by
which sevoflurane produced the dual effects. These re-
sults suggested that regulation of AKT/GSK3β by anes-
thetics or other perioperative factors might affect brain
function during surgery. The future studies to assess
whether short exposure time to sevoflurane (or other an-
esthetics) anesthesia attenuates, but long durations of
sevoflurane anesthesia potentiates, brain insults, e.g.,
cerebral ischemia, as well as studies to understand the
underlying mechanisms are needed.
The current studies have several limitations. First, we
did not determine the ratio of P-GSK3β(ser9) to total
Zhang et al. Medical Gas Research 2014, 4:5 Page 8 of 9
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However, the changes in the levels of P-GSK3β(ser9)
and P-AKT(ser473) are sufficient to reflect the changes
in the AKT/GSK3β signaling pathway [21-23]. Second,
we did not assess the downstream outcomes of the
AKT/GSK3β signaling pathway following the different
sevoflurane anesthesia. Such outcomes include many
cellular changes, and may take a long time to complete.
Third, different treatments with sevoflurane (e.g., once
every three days) and different time intervals of brain
harvest (three days after the sevoflurane anesthesia) may
have different findings in regards to the potential dual
effects of sevoflurane on brain function. However, such
studies may exceed the scope of the current experi-
ments, which aimed to establish a system and to gener-
ate a hypothesis for future studies. Nevertheless, the
current experiments have established the system and
demonstrated the effects of different sevoflurane
anesthesia on the activation of the AKT/GSK3β signal-
ing pathway. The future studies will employ the estab-
lished system to systematically determine the dual
effects of anesthetic sevoflurane on the AKT/GSK3β sig-
naling pathway, including the time course studies, and
investigation of the up-stream regulators and down-
stream consequences.
Conclusion
In conclusion, we found that anesthesia with 3% sevo-
flurane for two hours daily for one day increased the
levels of P-GSK3β(ser9) and P-AKT(ser473) in the brain
tissues of young mice, but the anesthesia with 3% sevo-
flurane for two hours daily for three days decreased the
levels. Similarly, the anesthesia with 4% sevoflurane for
two hours increased the levels of P-GSK3β(ser9) and P-
AKT(ser473) in the H4 cells, but the anesthesia with 4%
sevoflurane for six hours decreased them. These results
have suggested the dual effects of sevoflurane; that a
short duration of sevoflurane anesthesia activates, but a
long exposure to sevoflurane anesthesia inhibits, the
AKT/GSK3β signaling pathway. These findings have
established a system and have shown the potential dual
effects of sevoflurane anesthesia on the AKT/GSK3β sig-
naling pathway, which will likely promote more studies
to investigate the effects of sevoflurane on brain
function.
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